ABSTRACT
Glutaric aciduria type II (GAII) is a heterogeneous genetic disorder affecting mitochondrial fatty acid, amino acid and choline oxidation. Clinical manifestations vary across the lifespan and onset may occur at any time from the early neonatal period to advanced adulthood. Historically, some patients, in particular those with late onset disease, have experienced significant benefit from riboflavin supplementation. GAII has been considered an autosomal recessive condition caused by pathogenic variants in the gene encoding electron-transfer flavoprotein ubiquinone-oxidoreductase (ETFDH) or in the genes encoding electron-transfer flavoprotein subunits A and B (ETFA and ETFB respectively). Variants in genes involved in riboflavin metabolism have also been reported. However, in some patients, molecular analysis has failed to reveal diagnostic molecular results. In this study, we report the outcome of molecular analysis in 28 Australian patients across the lifespan, 10 paediatric and 18 adult, who had a diagnosis of glutaric aciduria type II based on both clinical and biochemical parameters. Whole genome sequencing was performed on 26 of the patients and two neonatal onset patients had targeted sequencing of candidate genes. The two patients who had targeted sequencing had biallelic pathogenic variants (in ETFA and ETFDH). None of the 26 patients whose whole genome was sequenced had biallelic variants in any of the primary candidate genes. Interestingly, nine of these patients (34.6%) had a monoallelic pathogenic or likely pathogenic variant in a single primary candidate gene and one patient (3.9%) had a monoallelic pathogenic or likely pathogenic variant in two separate genes within the same pathway. The frequencies of the damaging variants within ETFDH and FAD transporter gene SLC25A32 were significantly higher than expected when compared to the corresponding allele frequencies in the general population. The remaining 16 patients (61.5%) had no pathogenic or likely pathogenic variants in the candidate genes. Ten (56%) of the 18 adult patients were taking the selective serotonin reuptake inhibitor antidepressant sertraline, which has been shown to produce a GAII phenotype, and another two adults (11%) were taking a serotonin-norepinephrine reuptake inhibitor antidepressant, venlafaxine or duloxetine, which have a mechanism of action overlapping that of sertraline. Riboflavin deficiency can also mimic both the clinical and biochemical phenotype of GAII. Several patients on these antidepressants showed an initial response to riboflavin but then that response waned. These results suggest that the GAII phenotype can result from a complex interaction between monoallelic variants and the cellular environment. Whole genome or targeted gene panel analysis may not provide a clear molecular diagnosis.
Subject(s)
Electron-Transferring Flavoproteins , Multiple Acyl Coenzyme A Dehydrogenase Deficiency , Humans , Female , Male , Child , Adult , Child, Preschool , Electron-Transferring Flavoproteins/genetics , Adolescent , Multiple Acyl Coenzyme A Dehydrogenase Deficiency/genetics , Queensland , Riboflavin/therapeutic use , Young Adult , Infant , Iron-Sulfur Proteins/genetics , Cohort Studies , Oxidoreductases Acting on CH-NH Group Donors/genetics , Infant, Newborn , Mutation , Whole Genome SequencingABSTRACT
3-Hydroxy-3-Methylglutaryl-CoA Lyase (HMGCL) deficiency can be a very severe disorder that typically presents with acute metabolic decompensation with features of hypoketotic hypoglycemia, hyperammonemia, and metabolic acidosis. A retrospective chart and literature review of Australian patients over their lifespan, incorporating acute and long-term dietary management, was performed. Data from 10 patients contributed to this study. The index case of this disorder was lost to follow-up, but there is 100% survival in the remainder of the cases despite several having experienced life-threatening episodes. In the acute setting, five of nine patients have used 900 mg/kg/day of sodium D,L 3-hydroxybutyrate in combination with intravenous dextrose-containing fluids (delivering glucose above estimated basal utilization requirements). All patients have been on long-term protein restriction, and those diagnosed more recently have had additional fat restriction. Most patients take L-carnitine. Three children and none of the adults take nocturnal uncooked cornstarch. Of the cohort, there were two patients that presented atypically-one with fulminant liver failure and the other with isolated developmental delay. Dietary management in patients with HMGCL deficiency is well tolerated, and rapid institution of acute supportive metabolic treatment is imperative to optimizing survival and improve outcomes in this disorder.
Subject(s)
Amino Acid Metabolism, Inborn Errors , Hyperammonemia , Child , Adult , Humans , Retrospective Studies , Australia , Amino Acid Metabolism, Inborn Errors/therapyABSTRACT
BACKGROUND & AIM: PTC923 (formerly CNSA-001), an oral formulation of sepiapterin, a natural precursor of intracellular tetrahydrobiopterin (BH4), has been shown in humans to induce larger increases in circulating BH4 vs. sapropterin dihydrochloride. Sapropterin reduces blood phenylalanine (Phe) by ≥20-30% in a minority of subjects with PKU. This was a Phase 2 randomized, multicenter, three-period crossover, open-label, active controlled, all-comers [regardless of phenylalanine hydroxylase (PAH) variants] comparison of PTC923 60â¯mg/kg, PTC923 20â¯mg/kg and sapropterin 20â¯mg/kg in 24 adults with phenylketonuria (PKU) and hyperphenylalaninemia. METHODS: Eligible subjects were adult men or women (18-60 y) with PKU. Subjects enrolled received 7â¯days of once-daily oral treatment with PTC923 20â¯mg/kg/day, PTC923 60â¯mg/kg/day and sapropterin dihydrochloride 20â¯mg/kg/day each in a random order. Treatments were separated by a 7-day washout. Subjects maintained their usual pre-study diet, including consumption of amino acid mixtures. Blood Phe was measured on Day 1 (predose baseline), Day 3, Day 5, and Day 7 of each treatment period. RESULTS: Least squares mean changes (SE) from baseline in blood Phe were: -206.4 (41.8) µmol/L for PTC923 60â¯mg/kg (pâ¯<â¯0.0001); -146.9 (41.8) µmol/L for PTC923 20â¯mg/kg (pâ¯=â¯0.0010); andâ¯-â¯91.5 (41.7) µmol/L for sapropterin (pâ¯=â¯0.0339). Effects of PTC923 60â¯mg/kg on blood Phe vs. sapropterin were significantly larger (pâ¯=â¯0.0098) and faster in onset with a significantly larger mean reduction in blood Phe at day 3 of treatment, pâ¯=â¯0.0135 (20â¯mg/kg) and pâ¯=â¯0.0007 (60â¯mg/kg). Only PTC923 60â¯mg/kg reduced blood Phe in classical PKU subjects (nâ¯=â¯11, pâ¯=â¯0.0287). The mean blood Phe reduction (PTC923 60â¯mg/kg) in a cofactor responder analysis (nâ¯=â¯8; baseline Phe ≥300⯵mol/L and blood Phe reduction ≥30%) was -463.3⯵mol/L (SE 51.5) from baseline. Adverse events were mostly mild to moderate, transient, and similar across treatment groups with no serious adverse events or discontinuations. CONCLUSIONS: The substantially significantly better effect of PTC923 60â¯mg/kg on blood Phe reduction vs. sapropterin supports further clinical development of PTC923 for PKU; ANZCTR number, ACTRN12618001031257.
Subject(s)
Phenylalanine/blood , Phenylketonurias/drug therapy , Pterins/therapeutic use , Adolescent , Adult , Biopterins/analogs & derivatives , Biopterins/cerebrospinal fluid , Cross-Over Studies , Female , Humans , Male , Phenylalanine/administration & dosage , Phenylketonurias/blood , Pterins/adverse effects , Young AdultABSTRACT
Half of the mortality in diabetes is seen in individuals <50 years of age and commonly predicted by the early onset of diabetic kidney disease (DKD). In type 1 diabetes, increased urinary albumin-to-creatinine ratio (uACR) during adolescence defines this risk, but the pathological factors responsible remain unknown. We postulated that early in diabetes, glucose variations contribute to kidney injury molecule-1 (KIM-1) release from circulating T cells, elevating uACR and DKD risk. DKD risk was assigned in youth with type 1 diabetes (n = 100; 20.0 ± 2.8 years; males/females, 54:46; HbA1c 66.1 [12.3] mmol/mol; diabetes duration 10.7 ± 5.2 years; and BMI 24.5 [5.3] kg/m2) and 10-year historical uACR, HbA1c, and random blood glucose concentrations collected retrospectively. Glucose fluctuations in the absence of diabetes were also compared with streptozotocin diabetes in apolipoprotein E -/- mice. Kidney biopsies were used to examine infiltration of KIM-1-expressing T cells in DKD and compared with other chronic kidney disease. Individuals at high risk for DKD had persistent elevations in uACR defined by area under the curve (AUC; uACRAUC0-10yrs, 29.7 ± 8.8 vs. 4.5 ± 0.5; P < 0.01 vs. low risk) and early kidney dysfunction, including â¼8.3 mL/min/1.73 m2 higher estimated glomerular filtration rates (modified Schwartz equation; Padj < 0.031 vs. low risk) and plasma KIM-1 concentrations (â¼15% higher vs. low risk; P < 0.034). High-risk individuals had greater glycemic variability and increased peripheral blood T-cell KIM-1 expression, particularly on CD8+ T cells. These findings were confirmed in a murine model of glycemic variability both in the presence and absence of diabetes. KIM-1+ T cells were also infiltrating kidney biopsies from individuals with DKD. Healthy primary human proximal tubule epithelial cells exposed to plasma from high-risk youth with diabetes showed elevated collagen IV and sodium-glucose cotransporter 2 expression, alleviated with KIM-1 blockade. Taken together, these studies suggest that glycemic variations confer risk for DKD in diabetes via increased CD8+ T-cell production of KIM-1.
Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 1/blood , Diabetic Nephropathies/blood , Hepatitis A Virus Cellular Receptor 1/blood , Kidney/pathology , Adolescent , Adult , Diabetes Mellitus, Type 1/pathology , Diabetes Mellitus, Type 1/physiopathology , Diabetic Nephropathies/pathology , Diabetic Nephropathies/physiopathology , Female , Glomerular Filtration Rate/physiology , Humans , Kidney/physiopathology , Kidney Function Tests , Male , Retrospective Studies , Young AdultABSTRACT
AIM: This project aimed to implement consensus recommendations and innovations that improve dietetic services to promote timely referral to optimise nutritional management for adult inpatients with inborn errors of metabolism (IEM). METHODS: The i-PARIHS framework was used to identify service gaps, implement innovations and evaluate the innovations within this single-site study. The constructs of this framework are: (i) review of the evidence; (ii) recognising patients and staff knowledge and attitudes; (iii) acknowledging the local context; and (iv) the facilitators role. This included a literature review and metabolic centre service comparisons to investigate dietetic referral and foodservice processes to inform the innovation. A 12-month chart audit (6 months retrospective and prospective of implemented innovation, respectively) to evaluate newly established dietetic referral and IEM nutrition provision procedures was also completed. RESULTS: The innovations implemented encompassed a clinical alert triggering urgent referral, nutrition sick day plans and metabolic diet and formula prescription via an 'alert' tab in electronic records. Eleven metabolic protein-restricted diets and nine formula recipes were introduced. Prior to the innovations, only 53% (n = 19/36) of inpatients with IEM were assessed by the dietitian and received appropriate nutrition within 24 hours. Following implementation of the innovations, 100% (n = 11/11) of inpatients with IEM received timely dietetic assessment and therapeutic nutrition. CONCLUSIONS: Implementation of innovations developed using the i-PARIHS framework is effective in timely notification of the metabolic dietitian of referrals. This ensures optimal nutritional management during admissions which is required in this group of high-risk patients.
Subject(s)
Metabolism, Inborn Errors/diet therapy , Nutritional Status , Nutritional Support/standards , Nutritionists/standards , Outcome and Process Assessment, Health Care/standards , Quality Improvement/standards , Quality Indicators, Health Care/standards , Referral and Consultation/standards , Consensus , Diet, Protein-Restricted/standards , Food Service, Hospital/standards , Food, Formulated/standards , Humans , Inpatients , Metabolism, Inborn Errors/diagnosis , Metabolism, Inborn Errors/physiopathology , Program Evaluation , Prospective Studies , Retrospective Studies , Time Factors , Treatment OutcomeSubject(s)
Lipid Metabolism, Inborn Errors/diagnosis , Multiple Acyl Coenzyme A Dehydrogenase Deficiency/diagnosis , Muscular Dystrophies/diagnosis , Troponin I/blood , Troponin T/blood , Carnitine/analogs & derivatives , Carnitine/metabolism , Creatine Kinase/metabolism , Female , Humans , Lipid Metabolism, Inborn Errors/etiology , Middle Aged , Multiple Acyl Coenzyme A Dehydrogenase Deficiency/complications , Muscle Fatigue , Muscle, Skeletal/pathology , Muscular Dystrophies/etiology , Necrosis/etiologyABSTRACT
A primigravida was referred with hyperthyroidism in early pregnancy from longstanding Graves' disease treated with propylthiouracil. She had selective elevation of free tri-iodothyronine (fT3) levels, low normal free tetra-iodothyronine (fT4) and suppressed thyroid-stimulating hormone (TSH). Given her symptoms of thyrotoxicosis and elevated TSH receptor antibodies, therapy was tailored towards maintaining clinical and biochemical euthyroidism. However the fetus developed a goitre secondary to hypothyroidism. This case highlights the dilemmas in managing maternal T3 toxicosis while aiming for a high normal fT4 to prevent fetal hypothyroidism including the role of fetal ultrasound monitoring and amniocentesis.
ABSTRACT
INTRODUCTION: Adiponectin plays an important role in the regulation of tissue inflammation and insulin sensitivity. Perturbations in adiponectin concentration have been associated with obesity and the metabolic syndrome. Data on adiponectin pathophysiology in critical illness are limited. METHODS: Twenty three critically ill patients (9 severe sepsis, 7 burns, 7 trauma). Adiponectin assays on Days 3 (D3) and 7 (D7). Simultaneous, cortisol, cortisone and CRP measurements. Data from 16 historical controls were used for comparison. RESULTS: The mean plasma adiponectin concentration for the ICU cohort on D3 and D7 were not significantly different (4.1 +/- 1.8 and 5.0 +/- 3.3 mcg/ml respectively, P = 0.38). However, these were significantly lower than the mean plasma adiponectin in the control population (8.78 +/- 3.81 mcg/ml) at D3 (P < 0.0001) and D7 (P = 0.002). Plasma adiponectin showed a strong correlation with plasma cortisol in the ICU group on both D3 (R2 = 0.32, P < 0.01) and D7 (R2 = 0.64, 0.001). There was an inverse correlation between plasma adiponectin and CRP on D7, R = -0.35. CONCLUSIONS: In this preliminary study, critical illness was associated with lower adiponectin concentrations as compared with controls. A significant relationship between plasma cortisol and adiponectin in critically ill patients was evident, both during the early and late phases. These data raise the possibility that adiponectin may play a part in the inflammatory response in patients with severe illness.
Subject(s)
Adiponectin/blood , Burns/blood , Critical Illness , Sepsis/blood , Wounds and Injuries/blood , Adult , Aged , C-Reactive Protein/analysis , Case-Control Studies , Cortisone/blood , Female , Humans , Hydrocortisone/blood , Male , Middle Aged , RadioimmunoassayABSTRACT
Excess glucocorticoids induce insulin resistance and reduce glucose uptake although the underlying mechanisms are unclear. Here we demonstrate that Dex (1 microM for 24h) inhibits basal and insulin (1 nM) stimulated glucose uptake in human and murine adipocytes by 50% with a concomitant reduction in the levels of GLUT1/4 at the plasma membrane but no change in total GLUT1/4 levels. Expression and phosphorylation of proximal insulin signalling molecules (IRS1, PI3K, AKT) was unaffected by Dex as was phosphorylation of mTOR and FOXO1. In contrast, phosphorylation of AKT substrate 160kDa (AS160) at T642, which is essential for 14-3-3 recruitment and GLUT4 translocation, was reduced by 50% in basal and insulin-stimulated cells and this was mirrored by decreased 14-3-3 association. Co-treatment with the glucocorticoid receptor antagonist RU486 (10 microM) abrogated the Dex effect on AS160-T642 phosphorylation and restored glucose uptake by 80%. These data suggest Dex inhibits glucose uptake in adipocytes, at least in part, by reducing AS160 phosphorylation and interaction with 14-3-3.
Subject(s)
Adipocytes/metabolism , Carbohydrate Metabolism/drug effects , GTPase-Activating Proteins/metabolism , Gene Expression Regulation/drug effects , Glucocorticoids/pharmacology , Glucose/metabolism , 14-3-3 Proteins/metabolism , Animals , CHO Cells , Cells, Cultured , Cricetinae , Cricetulus , GTPase-Activating Proteins/antagonists & inhibitors , Glucocorticoids/metabolism , Humans , Insulin/physiology , Mice , Phosphorylation/drug effects , Protein Binding/drug effects , Signal Transduction/drug effectsABSTRACT
CONTEXT: Changes in cortisol metabolism due to altered activity of the enzyme 11beta-hydroxysteroid dehydrogenase (11beta-HSD) have been implicated in the pathogenesis of hypertension, obesity and the metabolic syndrome. No published data exist on the activity of this enzyme in critical illness. OBJECTIVE: To investigate cortisol metabolism in critically ill patients utilising plasma cortisol: cortisone ratio as an index of 11beta-HSD activity. SETTING: Tertiary level intensive care unit. PATIENTS: Three cohorts of critically ill patients: sepsis (n = 13); multitrauma (n = 20); and burns (n = 19). MAIN OUTCOME MEASURES: Serial plasma cortisol: cortisone ratios. MEASUREMENTS AND MAIN RESULTS: Plasma total cortisol cortisone ratios were determined serially after admission to the intensive care unit. As compared with controls, the plasma cortisol:cortisone ratio was significantly elevated in the sepsis and trauma cohorts on day 1 (22 +/- 9, p = 0.01, and 23 +/- 19, p = 0.0003, respectively) and remained elevated over the study period. Such a relationship was not demonstrable in burns. The ratio was significantly correlated with APACHE II (r = 0.77, p = 0.0008) and Simplified Acute Physiology Score (r = 0.7, p = 0.003) only on day 7 and only in the burns cohort. There were no significant correlations observed between total plasma cortisol or cortisone and sickness severity in the sepsis and trauma cohorts. CONCLUSIONS: In critically ill patients, there is evidence of altered cortisol metabolism due to an increase in 11beta-HSD activity as demonstrated by an elevation of plasma cortisol: cortisone ratios. Further studies with larger sample sizes specifically designed to examine altered tissue 11beta-HSD activity and its clinical significance and correlation with outcome are warranted.
Subject(s)
Critical Illness , Hydrocortisone/blood , Adult , Burns/metabolism , Cortisone/blood , Female , Humans , Intensive Care Units , Male , Middle Aged , Multiple Trauma/metabolism , Prospective Studies , Sepsis/metabolism , Shock, Septic/metabolismABSTRACT
Attention to known contraindications and intercurrent illness can avoid life-threatening acidosis.